首页> 外文OA文献 >OA11.07 Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for EGFR Mutation NSCLC Patients: Update Data for NCT02148380

【2h】

OA11.07 Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for EGFR Mutation NSCLC Patients: Update Data for NCT02148380

机译：OA11.07化疗加上EGFR-TKI作为一线治疗，为EGFR突变NSCLC患者提供更好的存活：NCT02148380更新数据

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
W. Zhang; J. Xu; Y. Lou; Y. Zhang; B. Han;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study [J] . Targeted oncology . 2020,第2期

机译：化疗加上EGFR-TKI作为一线治疗，为先进的EGFR阳性肺腺癌患者提供更好的存活：更新数据和体外研究探索
2. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism [J] . Liu Sangtian, He Yayi, Jiang Tao, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2018,第期

机译：EGFR-TKIS PLUS化疗在EGFR-TKIS中表现出优越的疗效，作为EGFR突变和BIM缺失多态性的先进NSCLC患者的一线设置。
3. P3.01-111 Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients with NSCLC Harboring Sensitive EGFR Mutations [J] . Y. Yamada, H. Imai, T. Sugiyama, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：P3.01-111患有敏感敏感EGFR突变的老年人EGFR-TKI后细胞毒性药物化疗的疗效和安全性
4. Intratumor Heterogeneity of EGFR Activating Mutations in Advanced NSCLC Patients at Single-Cell Level [C] . Liu Yuefen International Conference on Biomedical Engineering, Machinery and Earth Science . 2018

机译：单细胞水平晚期NSCLC患者EGFR激活突变的细胞内异质性
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [O] . Qiang Wu, Wuxia Luo, Wen Li, 2021

机译：第一代EGFR-TKI加上化疗与EGFR-TKI单独作为高级NSCLC的一线治疗具有EGFR激活突变：随机对照试验的系统评价和荟萃分析
7. First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: a systematic review and meta-analysis of randomized controlled trials [O] . Qiang Wu, Wuxia Luo, Wen Li, 2020

机译：第一代EGFR-TKI加上化疗与EGFR-TKI单独作为高级NSCLC的一线治疗，具有EGFR激活突变：随机对照试验的系统评价和荟萃分析

OA11.07 Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for EGFR Mutation NSCLC Patients: Update Data for NCT02148380

著录项

引文网络

相似文献

相关主题

期刊订阅